Navigation Links
INC Research and invivodata Announce ePRO Partnership

invivodata’s Regulatory Expertise Enhances CRO's Robust Global Service Offering

Raleigh, NC and Pittsburgh, PA (Vocus) March 4, 2010 -- INC Research®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results and invivodata®, inc., the industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a partnership in which invivodata provides its ePRO solutions and services as a component of INC’s full service offering portfolio. The partnership has evolved from the successful execution of multiple international clinical trials in which INC Research and invivodata clinical service teams have delivered ePRO solutions and services to global biopharmaceutical customers.

INC Research has unrivaled expertise and a reputation for conducting global clinical development programs of the highest integrity. With its focus on providing its customers fit for purpose solutions, INC Research continually assesses industry developments to adopt proven technologies into their complete range of customized clinical trial services.

“We chose to partner with invivodata based on the integration of scientific and regulatory principles into their ePRO solution - elements critical in ensuring high patient compliance and reliable data,” said Alistair Macdonald, INC Research’s executive vice president, Strategic Development. “By leveraging our relationship with invivodata, we can continue to guide our customers through any regulatory changes that may affect their research decisions, especially in light of the recent publication of the FDA's final PRO Guidance.”

invivodata combines scientific and regulatory expertise with practical technology and proactive services that enable clinical trial sponsors to confidently determine the effectiveness of new medical products and therapies. invivodata scientists and regulatory experts have long contributed to industry meetings that helped shape PRO guidance and have provided expertise to clinical researchers making key decisions about their PRO strategies for global clinical development programs.

"Having collaborated on multiple international clinical trials to date, invivodata and INC Research have developed synergies between our teams that drive real-world efficiencies in clinical research and better equip our customers to manage their clinical development processes," said Doug Engfer, invivodata president and CEO. “We’re eager to continue building on our long-term relationship with INC Research, and to help maximize the value they deliver to global biopharmaceutical organizations.”

About invivodata inc.
invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit

About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
2. Sorting device for analyzing biological reactions puts the power of a lab in a researchers pocket
3. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
4. New Source for Science Funding: BenchFly Pioneers Search for Research Program
5. Stem Cell Innovations to Provide Research and Assay Services to Agennix.
6. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
7. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
8. Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline
9. Stephen Coles is Recognized by Continental Whos Who Among Health Care Research Professionals
10. febits miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
11. Researchers gain detailed insight into failing heart cells using new nano technique
Post Your Comments:
Related Image:
INC Research and invivodata Announce ePRO Partnership
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):